FOXO Technologies
FOXO

$0.1500

3.6%

Market Cap: $2.04M

About: FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life.

Employees: 15

Industrials Commercial Physical & Biological Research

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2.0% less ownership

Funds ownership: 4.32% [Q1] → 2.31% (-2.0%) [Q2]

7% less capital invested

Capital invested by funds: $88.9K [Q1] → $83K (-$5.96K) [Q2]

8% less funds holding

Funds holding: 12 [Q1] → 11 (-1) [Q2]

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for FOXO.

See Analyst Rankings

Financial journalist opinion

FOXO Technologies Subsidiary, Myrtle Recovery Centers, Receives Two Full Licenses from the Tennessee Department of Mental Health and Substance Abuse Services

MINNEAPOLIS, MN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced that its recently acquired subsidiary, Myrtle Recovery Centers, Inc. (“Myrtle”), has been granted two full licenses from the Tennessee Department of Mental Health and Substance Abuse Services, effective August 1, 2024, for 12 months. The first license authorizes the provision of services for alcohol and drug residential detoxification treatment, as well as alcohol and drug residential rehabilitation treatment. The second license authorizes the provision of services for non-residential office-based opiate treatment.

FOXO Technologies Subsidiary, Myrtle Recovery Centers, Receives Two Full Licenses from the Tennessee Department of Mental Health and Substance Abuse Services

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

Reaffirms commitment to regaining compliance with the NYSE American continued listing standards Reaffirms commitment to regaining compliance with the NYSE American continued listing standards

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

FOXO Technologies Inc. Secures Up to $2.8 Million in Senior Notes to Fund Previously Announced Acquisition of Myrtle Recovery Centers, Inc. and Provide Additional Working Capital

MINNEAPOLIS, MN, June 18, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), today announced that it has secured up to $2.8 million in Senior Notes from an institutional investor (“Investor”) to fund the previously announced acquisition of Myrtle Recovery Centers, Inc. as well as provide additional working capital to support the Company's growth strategy.

FOXO Technologies Inc. Secures Up to $2.8 Million in Senior Notes to Fund Previously Announced Acquisition of Myrtle Recovery Centers, Inc. and Provide Additional Working Capital

FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc.

Acquisition expected to be synergistic with FOXO's epigenetic technology in community health and addiction recovery settings as well as contribute significant cash flow Acquisition expected to be synergistic with FOXO's epigenetic technology in community health and addiction recovery settings as well as contribute significant cash flow

FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc.

Why Is Foxo Technologies (FOXO) Stock Up 55% Today?

Foxo Technologies (NYSEMKT: FOXO ) stock is up on Friday after the epigenetic biomarkers technology company announced two acquisition deals. The first deal announced by Foxo Technologies is with Myrtle Recovery Centers.

Why Is Foxo Technologies (FOXO) Stock Up 55% Today?

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

Reaffirms commitment to regaining compliance with the NYSE American continued listing standards Reaffirms commitment to regaining compliance with the NYSE American continued listing standards

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

7 AI Penny Stocks to Double Your Money: February 2024

Penny stocks representing companies integrating AI into products and services hold particularly interesting upside. Penny Shares are known to move upward rapidly and the emergence of AI continues to produce rapid gains.

7 AI Penny Stocks to Double Your Money: February 2024

FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global

Proposed Combination to Focus on Securing Our Nation's Supply to Critical Materials and Resources Proposed Combination to Focus on Securing Our Nation's Supply to Critical Materials and Resources

FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global

FOXO Technologies Announces Appointment of Capital Markets Veteran Francis Colt deWolf to the Board of Directors

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced the appointment of Francis Colt deWolf to the Company's Board of Directors. Mr. deWolf III brings over 20 years of experience in the financial services Sector. He currently serves as President of Colt Capital LLC, a Florida-based company, whose principal activities focus on advising emerging market companies on private and public financing strategies. Prior to founding Colt Capital LLC, M.

FOXO Technologies Announces Appointment of Capital Markets Veteran Francis Colt deWolf to the Board of Directors

FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced it has formalized its collaboration with KR8.ai Inc. (“KR8”) and secured the exclusive license to KR8's AI-based software to support the development and commercial launch of its new health and wellness offering - the VITHAR™ AI Health Coach. As previously announced, the Company is in the process of launchi.

FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions

See News Rankings